Alterations in short-repetitive DNA sequences, known as
microsatellite instability (MSI), can reflect deficiencies in Mismatch Repair (MMR) system which represents a major player in
DNA integrity maintenance. The incidence of MSI-H/dMMR has been shown to be variable depending on the
tumor type. Several studies confirmed that dMMR/MSI status, although less frequent than PD-L1 expression, may better predict response to
immune-checkpoint inhibitors (ICIs) in patients with solid
tumors. In October 2016, the FDA granted
pembrolizumab as breakthrough
therapy for the treatment of non-CRC, MSI-H/dMMR
tumors, providing, for the first time, a
tumor-agnostic indication. In the next future, the tissue-agnostic evaluation of MSI-H/dMMR could become the common denominator for the
immunotherapy treatment of patients with different advanced solid
tumors, in order to select patient subgroups which may benefit from this
therapy. In this Review we provided an overview of the main clinical studies describing the association between MSI-H/dMMR
tumors and
immunotherapy response.